Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

非瓣膜病房颤口服抗凝药物中国专家建议

2014-08-01 亦晨 中华心血管病杂志血栓询证工作组

非瓣膜病心房颤动口服抗凝药物中国专家建议
关注

中国心房颤动(房颤)的特点是患病人数多且卒中发生率高，传统抗凝药物华法林使用比例及达标率低。无论是瓣膜病房颤还是非瓣膜病房颤，华法林是研究证据最充分、使用最普遍的口服抗凝药物，但由于剂量个体差异大、药物-药物或药物-食物相互作用常见，需频繁监测凝血指标，加上医生对华法林所致出血的过度担心，影响了其在临床实践中的广泛应用…… 非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家建议.pdf.p

中国心房颤动(房颤)的特点是患病人数多且卒中发生率高，传统抗凝药物华法林使用比例及达标率低。无论是瓣膜病房颤还是非瓣膜病房颤，华法林是研究证据最充分、使用最普遍的口服抗凝药物，但由于剂量个体差异大、药物-药物或药物-食物相互作用常见，需频繁监测凝血指标，加上医生对华法林所致出血的过度担心，影响了其在临床实践中的广泛应用……

非瓣膜病心房颤动患者应用新型口服抗凝药物中国专家建议.pdf.pdf


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2037928, encodeId=3c89203e928e5, content=<a href='/topic/show?id=0b8c38214e9' target=_blank style='color:#2F92EE;'>#口服抗凝药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38214, encryptionId=0b8c38214e9, topicName=口服抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Sun May 10 13:00:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819553, encodeId=b44b18195538a, content=<a href='/topic/show?id=3baf99548a8' target=_blank style='color:#2F92EE;'>#非瓣膜病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99548, encryptionId=3baf99548a8, topicName=非瓣膜病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun May 03 17:00:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377353, encodeId=c3f913e735316, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583439, encodeId=50621583439ea, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=)]
    2015-05-10 jingyanzhu715_39486101

    #口服抗凝药物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2037928, encodeId=3c89203e928e5, content=<a href='/topic/show?id=0b8c38214e9' target=_blank style='color:#2F92EE;'>#口服抗凝药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38214, encryptionId=0b8c38214e9, topicName=口服抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Sun May 10 13:00:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819553, encodeId=b44b18195538a, content=<a href='/topic/show?id=3baf99548a8' target=_blank style='color:#2F92EE;'>#非瓣膜病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99548, encryptionId=3baf99548a8, topicName=非瓣膜病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun May 03 17:00:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377353, encodeId=c3f913e735316, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583439, encodeId=50621583439ea, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=)]
    2015-05-03 tcm99hq

    #非瓣膜病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2037928, encodeId=3c89203e928e5, content=<a href='/topic/show?id=0b8c38214e9' target=_blank style='color:#2F92EE;'>#口服抗凝药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38214, encryptionId=0b8c38214e9, topicName=口服抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Sun May 10 13:00:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819553, encodeId=b44b18195538a, content=<a href='/topic/show?id=3baf99548a8' target=_blank style='color:#2F92EE;'>#非瓣膜病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99548, encryptionId=3baf99548a8, topicName=非瓣膜病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun May 03 17:00:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377353, encodeId=c3f913e735316, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583439, encodeId=50621583439ea, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=)]
    2014-08-03 hunizi005

    #口服抗凝药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2037928, encodeId=3c89203e928e5, content=<a href='/topic/show?id=0b8c38214e9' target=_blank style='color:#2F92EE;'>#口服抗凝药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38214, encryptionId=0b8c38214e9, topicName=口服抗凝药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3e72500135, createdName=jingyanzhu715_39486101, createdTime=Sun May 10 13:00:00 CST 2015, time=2015-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819553, encodeId=b44b18195538a, content=<a href='/topic/show?id=3baf99548a8' target=_blank style='color:#2F92EE;'>#非瓣膜病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99548, encryptionId=3baf99548a8, topicName=非瓣膜病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Sun May 03 17:00:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377353, encodeId=c3f913e735316, content=<a href='/topic/show?id=3098382134a' target=_blank style='color:#2F92EE;'>#口服抗凝药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38213, encryptionId=3098382134a, topicName=口服抗凝药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583439, encodeId=50621583439ea, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Sun Aug 03 05:00:00 CST 2014, time=2014-08-03, status=1, ipAttribution=)]
    2014-08-03 12498e5fm17(暂无昵称)

    #瓣膜#

    0

Baidu
map
Baidu
map
Baidu
map